CHICAGO — A real-world study of the ocular side effects of the gynecological cancer treatment mirvetuximab (Elahere) has ...

However, ocular toxicity was prevalent, leading to higher discontinuation rates in the experimental group. T-Duo is a third-generation HER2-targeted antibody-drug conjugate designed to treat HER2 ...

Corneal toxicity, visual acuity (VA), ocular therapeutic regimen, and ensuing changes in MIRV dose and spacing were recorded. The researchers found that 47, 22, and 31 percent of the 36 eyes had ...